Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn)

Antibiot Chemother (1971). 1996:48:147-54. doi: 10.1159/000425171.

Authors

E Guerra¹, G Ricci, M Carlesimo, A R Varani, O Pontesilli, E Scala, I Mezzaroma, Pierdominici, F Pandolfi, A Antinori, A De Luca, R Murri, A Ammassari, L Ortona, F Aiuti

Affiliation

¹ Department of Allergy and Clinical Immunology, University of Rome La Sapienza, Italy.

PMID: 8726519
DOI: 10.1159/000425171

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase II
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

AIDS Vaccines / administration & dosage*
AIDS Vaccines / immunology
Acquired Immunodeficiency Syndrome / immunology
Acquired Immunodeficiency Syndrome / therapy*
Adult
Antiviral Agents / administration & dosage
Combined Modality Therapy
Double-Blind Method
Female
HIV-1 / immunology*
Humans
Immunotherapy, Active
Male
Vaccines, Synthetic / administration & dosage*
Vaccines, Synthetic / immunology
Zidovudine / administration & dosage

Substances

AIDS Vaccines
Antiviral Agents
Vaccines, Synthetic
VaxSyn HIV-1 (gp160) vaccine
Zidovudine